1. Home
  2. BR vs UTHR Comparison

BR vs UTHR Comparison

Compare BR & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Broadridge Financial Solutions Inc.

BR

Broadridge Financial Solutions Inc.

HOLD

Current Price

$149.56

Market Cap

26.1B

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$562.09

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BR
UTHR
Founded
1962
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.1B
25.1B
IPO Year
2006
1999

Fundamental Metrics

Financial Performance
Metric
BR
UTHR
Price
$149.56
$562.09
Analyst Decision
Buy
Buy
Analyst Count
6
14
Target Price
$246.17
$567.57
AVG Volume (30 Days)
1.1M
357.6K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
2.43%
N/A
EPS Growth
21.16
13.07
EPS
6.18
5.82
Revenue
$4,142,600,000.00
$1,483,300,000.00
Revenue This Year
$10.04
$6.39
Revenue Next Year
$4.46
$14.18
P/E Ratio
$24.59
$98.27
Revenue Growth
N/A
2.38
52 Week Low
$149.05
$272.18
52 Week High
$271.91
$609.35

Technical Indicators

Market Signals
Indicator
BR
UTHR
Relative Strength Index (RSI) 33.27 48.29
Support Level N/A $560.16
Resistance Level $165.18 $600.77
Average True Range (ATR) 4.66 15.44
MACD -0.11 -2.26
Stochastic Oscillator 6.62 7.05

Price Performance

Historical Comparison
BR
UTHR

About BR Broadridge Financial Solutions Inc.

Broadridge Financial Solutions, which was spun off from Automatic Data Processing in 2007, is a leading provider of investor communication and technology-driven solutions to banks, broker/dealers, traditional and alternative-asset managers, wealth managers, and corporate issuers. Broadridge is composed of two operating segments: investor communication solutions and global technology and operations.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: